Department of Neurology, University Hospital Carl Gustav Carus Dresden, Technische Universität Dresden, 01307 Dresden, Germany.
Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), 01307 Dresden, Germany.
Cells. 2022 Apr 6;11(7):1246. doi: 10.3390/cells11071246.
Little is known about the early pathogenic events by which mutant superoxide dismutase 1 (SOD1) causes amyotrophic lateral sclerosis (ALS). This lack of mechanistic understanding is a major barrier to the development and evaluation of efficient therapies. Although protein aggregation is known to be involved, it is not understood how mutant SOD1 causes degeneration of motoneurons (MNs). Previous research has relied heavily on the overexpression of mutant SOD1, but the clinical relevance of SOD1 overexpression models remains questionable. We used a human induced pluripotent stem cell (iPSC) model of spinal MNs and three different endogenous ALS-associated mutations (D90A, R115G or A4V) to investigate early cellular disturbances in MNs. Although enhanced misfolding and aggregation of SOD1 was induced by proteasome inhibition, it was not affected by activation of the stress granule pathway. Interestingly, we identified loss of mitochondrial, but not lysosomal, integrity as the earliest common pathological phenotype, which preceded elevated levels of insoluble, aggregated SOD1. A super-elongated mitochondrial morphology with impaired inner mitochondrial membrane potential was a unifying feature in mutant SOD1 iPSC-derived MNs. Impaired mitochondrial integrity was most prominent in mutant D90A MNs, whereas both soluble disordered and detergent-resistant misfolded SOD1 was more prominent in R115G and A4V mutant lines. Taking advantage of patient-specific models of SOD1-ALS in vitro, our data suggest that mitochondrial dysfunction is one of the first crucial steps in the pathogenic cascade that leads to SOD1-ALS and also highlights the need for individualized medical approaches for SOD1-ALS.
目前对于突变超氧化物歧化酶 1(SOD1)导致肌萎缩侧索硬化症(ALS)的早期发病机制知之甚少。这种缺乏机制理解是开发和评估有效治疗方法的主要障碍。尽管已知蛋白聚集与此有关,但尚不清楚突变 SOD1 如何导致运动神经元(MNs)退化。以前的研究主要依赖于突变 SOD1 的过表达,但 SOD1 过表达模型的临床相关性仍存在疑问。我们使用人诱导多能干细胞(iPSC)脊髓 MN 模型和三种不同的内源性 ALS 相关突变(D90A、R115G 或 A4V)来研究 MNs 中的早期细胞紊乱。尽管蛋白酶体抑制诱导了 SOD1 的错误折叠和聚集增强,但应激颗粒途径的激活并没有影响到它。有趣的是,我们发现线粒体而非溶酶体完整性的丧失是最早的共同病理表型,它先于不溶性聚集 SOD1 水平的升高。超伸长线粒体形态和损伤的内膜电位是突变 SOD1 iPSC 衍生 MNs 的一个统一特征。在突变 D90A MNs 中,线粒体完整性受损最为明显,而在 R115G 和 A4V 突变系中,可溶性无序和去污剂抗性错误折叠的 SOD1 更为明显。利用体外 SOD1-ALS 的患者特异性模型,我们的数据表明,线粒体功能障碍是导致 SOD1-ALS 的致病级联反应中的第一个关键步骤之一,也突出了针对 SOD1-ALS 的个体化医疗方法的必要性。